Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
Methylation markers for glioma malignant progression identified by genome-wide methylation analysis were validated using MassARRAY. The result was highly correlated with Infinium methylation analysis. Many glioma samples, glioma cell line, and glioma stem cells were validated for the methylation markers. Methylation profile of glioma stem cells were similar to that of G-CIMP demethylated group, suggesting malignant progression with demethylation was related to glioma stemness. Demethylation sites in malignantly progressed samples were poorly enriched in Histon methylation marks such as H3K4me3 and H3K27me3 in embryonal stem cells.
|